Hereditary Hemochromatosis (HFE) genotypes in heart failure: Relation to etiology and prognosis by Møller, Daniel V et al.
RESEARCH ARTICLE Open Access
Hereditary Hemochromatosis (HFE) genotypes in
heart failure: Relation to etiology and prognosis
Daniel V Møller
1*, Redi Pecini
1, Finn Gustafsson
1, Christian Hassager
1, Paula Hedley
2, Cathrine Jespersgaard
2,
Christian Torp-Pedersen
3, Michael Christiansen
2, Lars V Køber
1,
EchoCardiography and Heart Outcome Study (ECHOS) investigators
1
Abstract
Background: It is believed that hereditary hemochromatosis (HH) might play a role in cardiac disease (heart failure
(HF) and ischemia). Mutations within several genes are HH-associated, the most common being the HFE gene. In a
large cohort of HF patients, we sought to determine the etiological role and the prognostic significance of HFE
genotypes.
Methods: We studied 667 HF patients (72.7% men) with depressed systolic function, enrolled in a multicentre trial
with a follow-up period of up to 5 years. All were genotyped for the known HFE variants C282Y, H63D and S65C.
Results: The genotype and allele frequencies in the HF group were similar to the frequencies determined in the
general Danish population. In multivariable analysis mortality was not predicted by C282Y-carrier status (HR 1.2,
95% CI: 0.8-1.7); H63D-carrier status (HR 1.0, 95% CI: 0.7-1.3); nor S65C-carrier status (HR 1.2, 95% CI: 0.7-2.0). We
identified 27 (4.1%) homozygous or compound heterozygous carriers of HFE variants. None of these carriers had a
clinical presentation suggesting hemochromatosis, but hemoglobin and ferritin levels were higher than in the rest
of the cohort. Furthermore, a trend towards reduced mortality was seen in this group in univariate analyses (HR
0.4, 95% CI: 0.2-0.9, p = 0.03), but not in multivariate (HR 0.5, 95% CI: 0.2-1.2).
Conclusion: HFE genotypes do not seem to be a significant contributor to the etiology of heart failure in
Denmark. HFE variants do not affect mortality in HF.
Background
Hereditary hemochromatosis (HH), an autosomal reces-
sive disease with incomplete penetrance and variable
expressivity, leads to progressive iron accumulation and
deposition in several organs including liver, pancreas
and in severe, untreated cases the heart. Clinically, HH
manifests as increased erythropoiesis, liver cirrhosis, dia-
betes mellitus, hepatocellular carcinoma and potentially
heart disease (heart failure, ischemia and arrhythmia,
especially in juvenile hemochromatosis) [1,2]. Mutations
within several genes have been associated with HH,
these include hemochromatosis (HFE), hemojuvelin
(HJV)[3], transferrin receptor 2 (TfR2)[4], and hepcidin
(HAMP)[5]. In 1996 the HFE gene was identified and
the C282Y and H63D polymorphisms associated with
HH[6]. Most HH-patients in Northern Europe are
C282Y homozygotes, and these account for 80-90% of
the HH cases, with compound heterozygotes (where an
individual has two different abnormal alleles at a parti-
cular locus) being responsible for an additional few per-
cent[7]. The biochemical prevalence of HH in Denmark
has been estimated to 0.37-0.46%[8] and 94.8% of diag-
nosed HH-patients are homozygous for the HFE C282Y
polymorphism[9].
Iron plays a variety of roles in cellular function and
variations in iron content could play a pathophysiologi-
cal role in several heart diseases due to interference in
oxidation-reduction reactions and cellular proliferation
[10]. HFE polymorphisms have been associated to the
occurrence of ischaemic heart disease[11], but this asso-
ciation is controversial and has not been confirmed in a
large meta-analysis[12]. Some studies concerning idio-
pathic dilated cardiomyopathy and HFE polymorphisms
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[13,14], whereas another, focusing on cardiomyopathies
of different etiologies, found that polymorphisms in the
HFE gene was associated with ischemic heart disease,
but there were neither biochemical markers nor survival
data available[15].
We hypothesized that HFE genotypes might play an
etiological role in heart failure (HF) or that variants in
HFE might modify the clinical prognosis of HF.
We explored this hypothesis in two ways. Firstly, we
examined the frequency of the most common HFE poly-
morphisms C282Y (dbSNP rs 1800562), H63D (dbSNP
rs 1799945) and S65C (dbSNP rs 1800730) in a large
HF population and assessed whether the HFE genotypes
C282Y/C282Y, H63D/H63D, S65C/S65C, C282Y/H63D,
C282Y/S65C and H63D/S65C, causing HH, were overre-
presented in HF, suggesting an etiological role. Secondly,
we studied the relation between different HFE genotypes
and all-cause mortality in the same population.
Methods
Subjects and clinical investigations
The study population was based on consecutive patients
enrolled in the Echocardiography and Heart Outcome
Study (ECHOS). ECHOS was a consecutive, prospective,
double-blind, randomized, placebo-controlled Scandina-
vian multicentre trial. It evaluated the effect of a selec-
tive agonist of the pre-synaptic DA2-dopaminergic and
a2-adrenergic receptors in patients with moderate to
severe heart failure of any etiology, with New York
Heart Association (NYHA) functional class II-IV. The
study was neutral with respect to every preselected end-
point and biological measure[16]. To be eligible for
inclusion in the study, patients were required to have a
history of dyspnoea or fatigue at rest or minimal exer-
tion, corresponding to NYHA class III-IV within the last
month, requiring treatment with diuretic and had to be
in NYHA class II-IV at time of randomization. Further-
more, an echocardiogram recorded at the local hospital
was evaluated in a core lab prior to randomization. To
be included, depressed left ventricular function corre-
sponding to wall motion index (WMI) ≤ 1.2 (using a
reverse scoring system; corresponding to a left ventricu-
lar ejection fraction ≤ 35%) had to be present[17].
Patients with acute coronary syndrome were not eligible
for the study nor were patients with atrioventricular
block grade II or III, clinically significant hepatic (severe
cirrhosis) or renal disease (serum creatinine > 300
μmol/l), stroke within 1 month, or any illness or disor-
der other than heart failure which could preclude parti-
cipation or severely limit survival. The local
investigators classified the patients in different groups
according to etiology as described previously[18]. The
study conforms to the principles outlined in the
Declaration of Helsinki and was approved by The Dan-
ish Board of Health as well as the Central Danish Ethics
Committee. All patients gave written informed consent.
There were 1000 patients randomized in the study. To
ensure long term mortality status, only Danish patients
with available blood samples were included in the pre-
sent study, leaving 667 patients available for genotyping
and follow up. Survival status was obtained from the
Danish Central Person Register, where all deaths are
registered within 2 weeks. The register was interrogated
in July 2006, resulting in a follow up period of up to
5 years. There were no HFE genotyped patients lost to
follow up.
Demographic data, NYHA class, left ventricular ejec-
tion fraction, medical history and medication at admis-
sion and at discharge as well as in-hospital
complications were recorded for all randomized
patients.
As the randomized study was neutral with regard to
every preselected endpoint and biological measure, we
made the present analysis without making any distinc-
tion between the two study treatment groups.
Molecular genetic studies
Genomic DNA was isolated from whole blood samples
using the Maxwell®16 system (Promega, USA). The
regions of HFE (Genbank accession no. NM_139011)
containing C282, H63 and S65 were amplified by poly-
merase chain reaction (primers available upon request).
Subsequently genotyping was performed by multiplex
pyrosequencing using the Pyro Gold Reagents kit (Bio-
tage, Uppsala, Sweden) and processed in a PSQ 96MA
(Biotage, Uppsala, Sweden).
Statistical analyses
Continuous variables are summarized as medians with
5
th and 95
th percentiles and group comparisons per-
formed by Wilcoxon rank sum test. Categorical variables
are expressed as number and percentage of the total
group and comparative analysis was done using the c
2-
test. Survival and event rates were determined with the
Kaplan-Meier method and comparisons between groups
were performed with the log rank test. Multivariable
analysis was performed using Cox proportional hazard
models. All variables, except medication, were included
in the multivariable analyses. In the Cox proportional
hazard model, BNP was logarithmic transformed. Each
HFE variant was dichotomized into carriers (hetero- and
homozygote carriers) and non-carriers due to small
sample size. We also evaluated the variables “any var-
iant” and “HH-genotype"; comparing any HFE variant
combination or genotypes associated to HH (C282Y/
C282Y, H63D/H63D, C282Y/H63D, C282Y/S65C and
H63D/S65C) to wild type of all three variants,
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a c
2-test with 6 degrees of freedom.
Data were analyzed using the Statistical Analysis Soft-
ware (SAS version 9.1). Results were considered signifi-
cant at p-value < 0.05.
Results
Clinical baseline characteristics of the 667 patients and
their HFE variant status are summarized in table 1. The
hemoglobin level in H63D carriers and the creatinine
level in S65C and “any variant"-carriers were higher
compared to non-carriers (p = 0.013; 0.025 and 0.04,
respectively). There were a lower frequency of patients
with a history of ischemic heart disease in the C282Y
carrier group as well as in the “any variant” carrier
group (p = 0.048 and 0.009). Otherwise there was no
statistically difference with respect to any of the vari-
ables between carriers and non-carriers.
Table 1 Clinical baseline characteristics of 667 patients hospitalized with symptomatic heart failure according to HFE
genotype
HFE variant C282Y H63D S65C Any variation
Status Carrier non-carrier Carrier non-carrier Carrier non-carrier Carrier Non-carrier
n total 73 594 144 523 26 641 231 436
Clinical data
Age (years) 72.0 (43.6-
86.8)
71.1 (49.5-
85.9)
71.3 (46.5-
87.8)
71.1 (49.5-
85.3)
72.6 (46.0-
80.6)
71.1 (48.4-
86.0)
71.5 (46.0-
87.1)
71.0 (50.0-
85.9)
male 55 (75) 430 (72) 106 (74) 379 (72) 18 (69) 467 (73) 170 (74) 315 (72)
BMI (kg/m
2) 26.4 (20.3-
35.1)
26.0 (18.8-
35.3)
26.4 (18.7-
34.4)
25.9 (19.2-
35.3)
26.0 (16.7-
44.7)
26.0 (19.1-
35.1)
26.3 (19.2-
35.1)
25.8 (19.1-
35.3)
Current smoker (%) 21 (29) 191 (33) 41 (29) 171 (33) 11 (44) 201 (32) 69 (30) 143 (33)
NYHA classes (%)
NYHA class I 1 (1) 21 (3) 7 (5) 10 (2) 0 17 (3) 8 (3) 9 (2)
NYHA class II 12 (16) 181 (28) 42 (29) 122 (23) 6 (23) 158 (25) 58 (25) 106 (24)
NYHA class III 47 (64) 360 (56) 76 (53) 315 (61) 15 (58) 376 (59) 132 (57) 259 (60)
NYHA class IV 13 (18) 80 (12) 19 (13) 73 (14) 5 (19) 87 (14) 33 (14) 59 (14)
Medical history
CHF (%) 62 (86) 502 (85) 115 (80) 449 (86) 23 (86) 541 (85) 189 (83) 375 (86)
IHD (%) 30 (41)* 317 (53) 65 (45) 282 (54) 14 (54) 333 (52) 104 (45)¤ 243 (56)
Former AMI (%) 23 (32) 217 (37) 51 (35) 189 (36) 9 (36) 231 (36) 78 (34) 162 (37)
Hypertension (%) 24 (33) 139 (23) 36 (25) 127 (24) 9 (35) 154 (24) 66 (29) 97 (22)
COPD (%) 14 (19) 127 (21) 31 (22) 110 (21) 8 (31) 133 (21) 52 (23) 89 (20)
Diabetes diagnosis (%) 13 (18) 102 (17) 25 (17) 90 (17) 7 (27) 108 (17) 42 (18) 73 (17)
Hyperlipidaemia (%) 22 (32) 217 (37) 50 (35) 189 (37) 9 (36) 230 (37) 76 (34) 163 (38)
Stroke/TCI (%) 14 (19) 70 (12) 16 (11) 68 (13) 6 (23) 78 (12) 34 (15) 50 (11)
Medication at
discharge
ACE-I (%) 52 (72) 474 (80) 115 (80) 411 (79) 20 (77) 506 (79) 178 (77) 348 (80)
AT-II blockers (%) 7 (10) 53 (9) 13 (9) 47 (9) 4 (15) 56 (9) 24 (10) 36 (8)
b-Blokage (%) 43 (60) 298 (50) 70 (49) 271 (52) 14 (54) 327 (51) 121 (53) 220 (51)
Diuretics (%) 71 (99) 578 (98) 142 (99) 507 (98) 25 (96) 624 (98) 226 (98) 423 (98)
Paraclinical data
WMI 1.0 (0.4-1.2) 0.9 (0.5-1.2) 0.9 (0.5-1.2) 0.9 (0.4-1.2) 0.9 (0.4-1.2) 0.9 (0.5-1.2) 0.9 (0.4-1.2) 0.9 (0.5-1.2)
Serum Ferritin (ng/ml) 121 (31-582) 123 (35-430) 129 (29-430) 122 (36-443) 159 (42-260) 121 (35-461) 127 (29-417) 121 (37-466)
Hemoglobin (mmol/l) 8.8 (7.1-10.8) 8.6 (6.7-10.4) 8.7 (7.0-10.4)† 8.6 (6.7-10.4) 8.4 (6.9-9.6) 8.6 (6.8-10.4) 8.7 (7.0-10.4)¶ 8.5 (6.6-10.4)
Serum creatinin (μmol/l) 99 (68-259) 106 (68-203) 108 (70-201) 104 (67-208) 120 (73-251)‡ 105 (68-198) 108 (68-222) 103 (67-194)
BNP (pmol/L) 1.5 (0.3-4.0) 1.3 (0.4-4.1) 1.3 (0.3- 3.7) 1.4 (0.4- 4.1) 1.3 (0.2- 4.7) 1.3 (0.4-4.0) 1.3 (0.3-4.2) 1.3 (0.4-4.0)
BMI = Body Mass Index; NYHA = New York Heart Association functional class; HF = Heart Failure; IHD = Ischemic Heart Disease; AMI = Acute Myocardial
Infarction; COPD = Chronic Obstructive Pulmonary Disease; TCI = Transient Cerebral Ischemia; ACE-I = Angiotensin Converting Enzyme-Inhibitor; AT-II =
Angiotensin II receptor; WMI = Wall Motion Index; BNP = Brain Natriuretic Peptide; * p = 0.046; † p = 0.007; ‡ p = 0.025; ¤ p = 0.002; ¶ p = 0.022
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in conjunction with a newly published result obtained in
a large Danish general population cohort[19] and is con-
sistent with the Hardy-Weinberg equilibrium (c
2 = 1.97,
p = 0.922). No significant differences were found
between the two populations.
We found 231 (34.6%) of the patients to carry at least
one of the three HFE polymorphisms. The allele fre-
quencies of HFE polymorphisms C282Y, H63D and
S65C were 5.7%, 11.7% and 1.9%, respectively. We
found homozygosity in three patients for C282Y, in 12
for H63D and none for S65C. Compound heterozygosity
was present in 12 patients. Thus, 27 patients had a gen-
otype suggestive of HH. None of the homozygotes had
markedly elevated serum ferritin (all < 1000 ng/ml),
while one compound heterozygote (C282Y/H63D) had
markedly elevated serum ferritin level (1528 ng/ml).
Median ferritin level was significantly higher among the
27 patients, compared to non-carriers (p = 0.021). None
had a history of HH, nor developed it during the follow
up period.
The homozygotes and compound heterozygotes had a
significantly lower mortality (p = 0.019) when compared
with the rest of the patients in univariate analyses (HR
0.4, 95% CI: 0.2-0.9). The significance diminished in
multivariable analyses, leaving it insignificant (HR 0.5,
95% CI: 0.2-1.2). The genotypes associated with HH had
significantly higher levels of serum ferritin, but not to
an extent believed to cause organ damage. In the three
C282Y homozygotes, which carry the presumably high-
est risk of developing HH, we examined hospital records
to explore the possibility of a missed HH-diagnosis.
Ferritin levels were normal (< 300 ng/ml) in all three
patients (two men). One suffered from diabetes, while
two had cerebral stroke as well as atrial fibrillation. Two
of them had died, at the ages 80 and 98 years, respec-
tively. The last one, a male age 80 years old is still alive.
None of them had liver involvement or a history of skin
pigmentation. There were no clinically indices support-
ing the HH diagnosis. However, no histological material
was available to exclude iron deposition.
Table 3 summarizes the distribution of the etiologies
of HF (where known) as a function of carrier or non-
carrier status for each polymorphism. No association
between polymorphisms and etiology was found. The
relation between variant carrier status and mortality
during the follow-up period (median 51 months (range:
33.6 - 64.6 months, 328 deaths (49.2%)) is also given
and the S65C polymorphism is associated with signifi-
cantly (p = 0.017) increased mortality. Univariate Cox
proportional hazards analyses was performed to assess
the impact of different HFE genotypes and their carrier-
status on all-cause mortality. Only the S65C carrier sta-
tus was a significant predictor of all-cause mortality (HR
1.9, 95% CI: 1.2-3.0). In multivariable Cox proportional
hazard analyses the impact on all-cause mortality
decreased, leaving it insignificant (HR 1.2, 95% CI: 0.7-
2.0). Serum ferritin was not associated with mortality
(HR 1.00; 95% CI: 0.99-1.01, p = 0.88). Significant pre-
dictors were: age (HR 1.03, 95% CI: 1.02-1.04); diabetes
(HR 1.31, 95% CI: 1.00-1.75); history of stroke (HR 1.39,
95% CI: 1.01-1.91); hemoglobin-level (HR 0.88, 95% CI:
0.78-1,00); BNP (HR 1.38, 95% CI: 1.21-1.58) and
chronic obstructive pulmonary disorder (HR 2,08, 95%
CI: 1.60-2.70).
Discussion
The present study demonstrates in a large population
hospitalized for symptomatic heart failure that the dis-
tribution of HFE polymorphisms C282Y, H65D and
S63C is not dissimilar from the distribution found in
the general Danish male population and that HFE geno-
types is not a significant etiological factor in heart fail-
ure. None of the HFE polymorphisms carried
independent prognostic information, but homozygotes
or compound heterozygotes, despite having increased
risk of HH, had a trend towards reduced mortality.
The hemochromatosis gene encodes HFE,at r a n s -
membrane glycoprotein which normally associates with
transferrin receptor 1 (TfR1) and decreases intracellular
iron and ferritin concentrations. New insights into the
function of the HFE p r o t e i ns u g g e s t sa ni r o ns e n s i n g
function, as well as a hepcidin regulating function[20]
and subsequently a pivotal role in iron homeostasis. The
C282Y polymorphism disrupts the TfR1 association
leading to accumulation of intracellular iron and loss of
Table 2 Distribution of HFE genotypes in 667 heart
failure patients, compared to frequencies found among
6020 Danish men (Pedersen et al.[19]) showing no
differences between the two studies
Genotype Distribution Pedersen et al
[19]
C282Y H63D S65C n n
expected*
(%) of
total†
(%)/n
C/C H/H S/S 436 434 65.4 64.3/3871
Y/C H/H S/S 61 61 9.2 8.4/503
Y/C D/H S/S 8 9 1.2 1.4/85
Y/C H/H C/S 1 2 0.2 0.1/9
Y/Y H/H S/S 3 2 0.4 0.4/23
C/C D/H S/S 121 126 18.1 20.1/1208
C/C D/H C/S 3 3 0.4 0.4/27
C/C D/D S/S 12 9 1.8 1.8/110
C/C H/H C/S 22 21 3.3 3.0/183
C/C H/H C/C 0 0 0 0/1
Total 667 667 100 100/6020
* according to Hardy-Weinberg equilibrium; † of observed
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H63D and S65C influence iron homeostasis has not yet
been clarified, as they do not interrupt the TfR1 associa-
tion. All three polymorphisms are associated with HH
[21] with variable disease expression and penetrance.
The HFE H63D polymorphism also associates with neu-
rodegenerative disorders[22] and cerebral stroke[23]
among others. We confirm the lack of association
between HFE polymorphisms and IHD in our material,
as well as confirming the lack of association with dilated
cardiomyopathy. In addition, we found no association
between the remaining etiologies to heart failure and
the frequencies of the HFE polymorphisms.
Hereditary hemochromatosis has been described as a
potential cause of heart failure and arrhythmias[24] and
as a consequence we assessed a large heart failure popu-
lation with different etiology using HFE genotyping and
serum ferritin measurements. The distribution of HFE
genotypes was similar to prior Danish studies[19] indi-
cating that the role of HH appears low. The well known
variable biochemical and clinical expressivity of the
homozygote C282Y polymorphism can explain the dis-
crepancy found between the frequency of C282Y homo-
zygotes in the general population and HH[25]. The
concurrence of genetic and nongenetic factors in the
development of HH due to HFE polymorphisms seems
present. Studies investigating modifiers of the pene-
trance in HFE related hemochromatosis has been con-
flicting in humans[26,27] despite convincing animal
models[28].
To our knowledge, this is the first study that examines
HFE-polymorphisms and their association with all-cause
mortality in a heart failure population. Dunn et al[29]
found no association between HFE polymorphisms and
cardio-vascular disease mortality in patients with coron-
ary artery disease. In our study we found no association
between HFE genotype and all-cause mortality irrespec-
tive of heart failure etiology including ischemic heart
disease and dilated cardiomyopathy. Although we did
not specify the cause of death to be cardiac or non-car-
d i a cr e l a t e da st h es t u d yb yn a t u r ei so b s e r v a t i o n a l ,a l l
patients suffered from severe heart failure (NYHA class
III-IV episode within a month prior to inclusion) why
the main cause of death should be expected to be due
to cardiovascular disorders. This fits well with prior
investigations performed where cardiac mortality rates
of about 50% over a 5-year period in HF-patients is seen
[30]. The S65C polymorphism seemed to significantly
increase mortality when tested in univariate analyses
and keeping in mind the low number in this group it
lost its significance when applying available covariates.
The significantly higher hemoglobin level seen in the
“HH-genotype” group could explain the tendency
towards decreased mortality seen in the group. It is well
established that anemia in heart failure increases mortal-
ity[31] It could be speculated that the HFE genotypes
predisposing HH, in our population represents a mild
clinical form, not leading to organ damage but only
altering hepcidin levels leading to increased erythropoi-
esis. Univariate analyses were significant, but due to the
small sample size (27 patients) especially with the
C282Y homozygous polymorphism (3 patients) we did
not have enough statistical power to make any definite
conclusions.
Patients with severe liver affection, i.e. biochemical
suspicion of cirrhosis of the liver, were excluded from
the study ruling out the presence of overt classical HH.
Subsequently, we investigated the role of the various
HFE genotypes. A possible source of bias could be the
exclusion of patients with cerebral stroke within the last
month as Ellervik et al[23] found a positive association
between HFE genotypes and stroke. Thereby we could
have lost patients, with a HFE genotype but without
overt HH, although the amount of patients missed must
be negligible, given the low frequency of HH. Further-
more, none of the excluded patients was diagnosed with
H Hd u r i n gt h ef o l l o wu pp e r i o da s s e s s e db yt h eD a n i s h
Patient Register.
Table 3 HFE genotype distribution according to etiology and mortality
Variant Genotype Distribution IHD
(n = 332)
Hypertension
(n = 61)
DCM
(n = 108)
Valve disease
(n = 42)
Other
(n = 57)
Unknown
(n = 67)
Deceased
(n = 328) (%)
C282Y Non-carrier 594 303 (51.0) 51 (8.6) 93 (15.7) 38 (6.4) 49 (8.3) 60 (10.1) 290 (48.8)
Carrier 73 29 (39.7) 10 (13.7) 15 (20.6) 4 (5.5) 8 (11.0) 7 (9.6) 38 (52.0)
H63D Non-carrier 523 268 (51.2) 46 (8.8) 80 (15.3) 35 (6.7) 39 (7.5) 55 (10.5) 263 (50.3)
Carrier 144 64 (44.4) 15 (10.4) 28 (19.4) 7 (4.9) 18 (12.5) 12 (8.3) 65 (45.1)
S65C Non-carrier 641 318 (49.6) 59 (9.2) 104 (16.2) 41 (6.4) 54 (8.4) 65 (10.1) 309 (48.2)
Carrier 26 14 (53.9) 2 (7.7) 4 (15.4) 1 (3.9) 3 (11.5) 2 (7.7) 19 (73.1)*
Any Non-carrier 436 230 (52.8) 35 (8.0) 65 (14.9) 30 (6.9) 30 (6.9) 46 (10.6) 210 (48.2)
Carrier 231 102 (44.2) 26 (11.3) 43 (18.6) 12 (5.2) 27 (11.7) 21 (9.1) 118 (51.1)
DCM = dilated cardiomyopathy, IHD = ischemic heart disease, Other = HF due to atrial fibrillation or rare diseases, Unknown = no single disease could be
assigned as the cause of HF, Deceased = deceased in the follow up period, *p = 0.019
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In conclusion, HFE genotypes were not associated with
systolic heart failure, irrespective of etiology. Secondly,
HFE genotypes did not significantly affect prognosis.
Therefore, it seems that performing HFE genotype
screening in heart failure patients has no value, unless
they display clear clinical signs of HH, including bio-
chemical markers as elevated serum ferritin, transferrin
saturation and in the future possibly also decreased hep-
cidin levels. Future studies should evaluate if certain
HFE genotypes could have a modifying effect on heart
failure mortality due to the effect on hepcidin and sub-
sequently hemoglobin levels.
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